As on Wednesday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) started slowly as it slid -5.94% to $8.24, before settling in for the price of $8.76 at the close. Taking a more long-term approach, KALV posted a 52-week range of $7.97-$16.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -24.26% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -20.06%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -5.39%. This publicly-traded company’s shares outstanding now amounts to $43.27 million, simultaneously with a float of $34.67 million. The organization now has a market capitalization sitting at $407.20 million. At the time of writing, stock’s 50-day Moving Average stood at $9.66, while the 200-day Moving Average is $11.46.
KalVista Pharmaceuticals Inc (KALV) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. KalVista Pharmaceuticals Inc’s current insider ownership accounts for 29.84%, in contrast to 73.96% institutional ownership. According to the most recent insider trade that took place on Dec 09 ’24, this organization’s CHIEF EXECUTIVE OFFICER sold 7,627 shares at the rate of 9.75, making the entire transaction reach 74,363 in total value, affecting insider ownership by 274,596. Preceding that transaction, on Nov 26 ’24, Company’s CHIEF MEDICAL OFFICER sold 2,187 for 9.87, making the whole transaction’s value amount to 21,586. This particular insider is now the holder of 97,012 in total.
KalVista Pharmaceuticals Inc (KALV) Earnings and Revenue Records
KalVista Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -5.39% and is forecasted to reach -2.76 in the upcoming year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Let’s observe the current performance indicators for KalVista Pharmaceuticals Inc (KALV). It’s Quick Ratio in the last reported quarter now stands at 6.87. The Stock has managed to achieve an average true range (ATR) of 0.52.
In the same vein, KALV’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.64, a figure that is expected to reach -0.87 in the next quarter, and analysts are predicting that it will be -2.76 at the market close of one year from today.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Through scrutinizing the latest numbers posted by the [KalVista Pharmaceuticals Inc, KALV], it can be observed that its last 5-days Average volume of 0.2 million was better the volume of 0.2 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 37.58% While, its Average True Range was 0.49.
Raw Stochastic average of KalVista Pharmaceuticals Inc (KALV) in the period of the previous 100 days is set at 4.86%, which indicates a major fall in contrast to 20.30% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.38% that was lower than 67.11% volatility it exhibited in the past 100-days period.
